Kairos Pharma, Ltd. (KAPA)

Kairos Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	3.83	1.93	1.63	0.48	1.76
Research & Development	1.77	0.41	0.08	0.09	0.18
Operating Expenses	5.6	2.34	1.71	0.57	1.94
Operating Income	-5.6	-2.34	-1.71	-0.57	-1.94
Interest Expense	-	-0.19	-0.1	-0.46	-0.16
Other Non Operating Income (Expenses)	-0.13	-0.67	-	-0.02	-0.04
EBT Excluding Unusual Items	-5.66	-3.2	-1.81	-1.05	-2.15
Other Unusual Items	0.6	0.6	-	-	-
Pretax Income	-5.06	-2.6	-1.81	-1.05	-2.15
Net Income	-5.06	-2.6	-1.81	-1.05	-2.15
Net Income to Common	-5.06	-2.6	-1.81	-1.05	-2.15
Shares Outstanding (Basic)	17	11	10	10	9
Shares Outstanding (Diluted)	17	11	10	10	9
Shares Change (YoY)	55.64%	9.38%	1.42%	11.86%	-
EPS (Basic)	-0.31	-0.23	-0.17	-0.10	-0.23
EPS (Diluted)	-0.31	-0.23	-0.17	-0.10	-0.23
EBITDA	-5.44	-2.18	-1.55	-0.41	-1.85
D&A For EBITDA	0.16	0.16	0.16	0.16	0.1
EBIT	-5.6	-2.34	-1.71	-0.57	-1.94

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q